Document:

Exhibit 10.2

 

 

Note Purchase Agreement

 

This
Note Purchase Agreement (this “Agreement”), dated as of May 20, 2022, is entered into by and among Nemaura
Medical Inc., a Nevada corporation (“Company”), Dermal Diagnostics Limited,
an England and Wales corporation (“Dermal Diagnostics”), Trial Clinic Limited,
an England and Wales corporation (“Trial Clinic”, and together with Dermal Diagnostics and Company, “Borrower”),
and Streeterville Capital, LLC, a Utah limited liability company, its successors and/or
assigns (“Investor”).

A.Borrower
and Investor are executing and delivering this Agreement in reliance upon an exemption from securities registration afforded by the Securities
Act of 1933, as amended (the “1933 Act”), and the rules and regulations promulgated thereunder by the United States
Securities and Exchange Commission (the “SEC”).

B.Investor
desires to purchase and Borrower desires to issue and sell, upon the terms and conditions set forth in this Agreement, a Secured Promissory
Note, in the form attached hereto as Exhibit A, in the original principal amount of $6,015,000.00 (the “Note”).

C.Dermal
Diagnostics and Trial Clinic are subsidiaries of Company that (i) are involved in Company’s ongoing operations, (ii) hold and/or
control various assets, and (iii) are co-borrowers under the Note.

D.The
proceeds from the Note will provide substantial benefits to each of Company, Dermal Diagnostics and Trial Clinic.

E.This
Agreement, the Note, the Security Agreement (as defined below), and all other certificates, documents, agreements, resolutions and instruments
delivered to any party under or in connection with this Agreement, as the same may be amended from time to time, are collectively referred
to herein as the “Transaction Documents”.

NOW, THEREFORE,
in consideration of the above recitals and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
Company and Investor hereby agree as follows:

1.
Purchase and Sale of Note.

1.1.
Purchase of Note. Borrower shall issue and sell to Investor and Investor shall purchase from
Borrower the Note. In consideration thereof, Investor shall pay the Purchase Price (as defined below) to Borrower.

1.2.
Form of Payment. On the Closing Date (as defined below), Investor shall pay the Purchase Price
to Borrower via wire transfer of immediately available funds against delivery of the Note.

1.3.
Closing Date. Subject to the satisfaction (or written waiver) of the conditions set forth
in Section 5 and Section 6 below, the date of the issuance and sale of the Note pursuant to this Agreement (the “Closing Date”)
shall be May 20, 2022, or another mutually agreed upon date. The closing of the transactions contemplated by this Agreement (the “Closing”)
shall occur on the Closing Date by means of the exchange by email of .pdf documents, but shall be deemed for all purposes to have occurred
at the offices of Hansen Black Anderson Ashcraft PLLC in Lehi, Utah.

1.4.
Collateral for the Note. The Note shall be secured by the collateral set forth in that certain
Security Agreement attached hereto as Exhibit B listing all of Borrower’s assets as security for Borrower’s obligations
under the Transaction Documents (the “Security Agreement”). 

1.5.
Original Issue Discount; Transaction Expense Amount. The Note carries an original issue discount
of $1,000,000.00 (the “OID”). In addition, Borrower agrees to pay $15,000.00 to Investor to cover Investor’s
legal fees, accounting costs, due diligence, monitoring and other transaction costs incurred in connection with the purchase and sale
of the Note (the “Transaction Expense Amount”), all of which amount is included in the initial principal balance of
the Note. The “Purchase Price”, therefore, shall be $5,000,000.00, computed as follows: $6,015,000.00 initial principal
balance, less the OID, less the Transaction Expense Amount. 

 

    	1 

    	 

    

2.
Investor’s Representations and Warranties. Investor represents and warrants to Borrower
that as of the Closing Date: (i) this Agreement has been duly and validly authorized; (ii) this Agreement constitutes a valid and binding
agreement of Investor enforceable in accordance with its terms; and (iii) Investor is an “accredited investor” as that term
is defined in Rule 501(a) of Regulation D of the 1933 Act.

3.
Borrower Representation and Warranties.

3.1.
Company’s Representations and Warranties. Company represents and warrants to Investor
that as of the Closing Date: (i) Company is a corporation duly organized, validly existing and in good standing under the laws of its
state of incorporation and has the requisite corporate power to own its properties and to carry on its business as now being conducted;
(ii) Company is duly qualified as a foreign corporation to do business and is in good standing in each jurisdiction where the nature of
the business conducted or property owned by it makes such qualification necessary; (iii) Company has registered its shares of common stock,
$0.001 per share (the “Common Stock”), under Section 12(g) of the Securities Exchange Act of 1934, as amended
(the “1934 Act”), and is obligated to file reports pursuant to Section 13 or Section 15(d) of the 1934 Act;
(iv) each of the Transaction Documents and the transactions contemplated hereby and thereby, have been duly and validly authorized by
Company and all necessary actions have been taken; (v) this Agreement, the Note, the Security Agreement, and the other Transaction Documents
have been duly executed and delivered by Company and constitute the valid and binding obligations of Company enforceable in accordance
with their terms; (vi) the execution and delivery of the Transaction Documents by Company and the consummation by Company of the other
transactions contemplated by the Transaction Documents do not and will not conflict with or result in a breach by Company of any of the
terms or provisions of, or constitute a default under (a) Company’s certificate of incorporation or bylaws, each as currently in
effect, (b) any indenture, mortgage, deed of trust, or other material agreement or instrument to which Company is a party or by which
it or any of its properties or assets are bound, or (c) any existing applicable law, rule, or regulation or any applicable decree, judgment,
or order of any court, United States federal, state or foreign regulatory body, administrative agency, or other governmental body having
jurisdiction over Company or any of Company’s properties or assets; (vii) no further authorization, approval or consent of any court,
governmental body, regulatory agency, self-regulatory organization, or stock exchange or market or the stockholders or any lender of Company
is required to be obtained by Company for the issuance of the Note to Investor or the entering into of the Transaction Documents; (viii)
none of Company’s filings with the SEC contained, at the time they were filed, any untrue statement of a material fact or omitted
to state any material fact required to be stated therein or necessary to make the statements made therein, in light of the circumstances
under which they were made, not misleading; (ix) Company has filed all reports, schedules, forms, statements and other documents required
to be filed by Company with the SEC under the 1934 Act on a timely basis or has received a valid extension of such time of filing and
has filed any such report, schedule, form, statement or other document prior to the expiration of any such extension; (x) there is no
action, suit, proceeding, inquiry or investigation before or by any court, public board or body pending or, to the knowledge of Company,
threatened against Company before or by any governmental authority or non-governmental department, commission, board, bureau, agency or
instrumentality or any other person; (xi) Company has not consummated any financing transaction that has not been disclosed in a periodic
filing or current report with the SEC under the 1934 Act; (xii) Company is not, nor has it been at any time in the previous twelve (12)
months, a “Shell Company,” as such type of “issuer” is described in Rule 144(i)(1) under the 1933 Act; (xiii)
Investor shall have no obligation with respect to any commissions, placement agent or finder’s fees or similar payments (“Broker
Fees”) or with respect to any claims made by or on behalf of other persons for fees of a type contemplated in this subsection
that may be due in connection with the transactions contemplated hereby and Company shall indemnify and hold harmless each of Investor,
Investor’s employees, officers, directors, stockholders, managers, agents, and partners, and their respective affiliates, from and
against all claims, losses, damages, costs (including the costs of preparation and attorneys’ fees) and expenses suffered in respect
of any such claimed or existing Broker Fees; (xiv) neither Investor nor any of its officers, directors, members, managers, employees,
agents or representatives has made any representations or warranties to Company or any of its officers, directors, employees, agents or
representatives except as expressly set forth in the Transaction Documents and, in making its decision to enter into the transactions
contemplated by the Transaction Documents, Company is not relying on any representation, warranty, covenant or promise of Investor or
its officers, directors, members, managers, employees, agents or representatives other than as set forth in the Transaction Documents;
(xv) Company acknowledges that the State of Utah has a reasonable relationship and sufficient contacts to the transactions contemplated
by the Transaction Documents and any dispute that may arise related thereto such that the laws and venue of the State of Utah, as set
forth more specifically in Section 8.2 below, shall be applicable to the Transaction Documents and the transactions contemplated therein;
(xvi) the proceeds from the Note will provide substantial benefits to Company; (xvii) Company acknowledges that Investor is not registered
as a ‘dealer’ under the 1934 Act; and (xviii) Company has performed due diligence and background research on Investor and
its affiliates and has received and reviewed the due diligence packet provided by Investor. Company, being aware of the matters and legal
issues described in subsections (xvii) and (xviii) above, acknowledges and agrees that such matters, or any similar matters, have no bearing
on the transactions contemplated by the Transaction Documents and covenants and agrees it will not use any such information or legal theory
as a defense to performance of its obligations under the Transaction Documents or in any attempt to avoid, modify, reduce, rescind or
void such obligations.

    	2 

    	 

    

3.2.
Dermal Diagnostics Representations and Warranties. Dermal Diagnostics represents and warrants
to Investor that as of the Closing Date: (i) Dermal Diagnostics is a corporation duly organized, validly existing and in good standing
under the laws of its state of incorporation and has the requisite corporate power to own its properties and to carry on its business
as now being conducted; (ii) Dermal Diagnostics is duly qualified as a foreign corporation to do business and is in good standing in each
jurisdiction where the nature of the business conducted or property owned by it makes such qualification necessary; (iii) each of the
Transaction Documents and the transactions contemplated hereby and thereby, have been duly and validly authorized by Dermal Diagnostics
and all necessary actions have been taken; (iv) this Agreement, the Note, the Security Agreement and the other Transaction Documents have
been duly executed and delivered by Dermal Diagnostics and constitute the valid and binding obligations of Dermal Diagnostics enforceable
in accordance with their terms; (v) the execution and delivery of the Transaction Documents by Dermal Diagnostics and the consummation
by Dermal Diagnostics of the other transactions contemplated by the Transaction Documents do not and will not conflict with or result
in a breach by Dermal Diagnostics of any of the terms or provisions of, or constitute a default under (a) Dermal Diagnostics’ formation
documents or bylaws, each as currently in effect, (b) any indenture, mortgage, deed of trust, or other material agreement or instrument
to which Dermal Diagnostics is a party or by which it or any of its properties or assets are bound, or (c) any existing applicable law,
rule, or regulation or any applicable decree, judgment, or order of any court, United States federal, state or foreign regulatory body,
administrative agency, or other governmental body having jurisdiction over Dermal Diagnostics or any of Dermal Diagnostics’ properties
or assets; (vi) no further authorization, approval or consent of any court, governmental body, regulatory agency, self-regulatory organization,
or stock exchange or market or the stockholders or any lender of Dermal Diagnostics is required to be obtained by Dermal Diagnostics for
the issuance of the Note to Investor or the entering into of the Transaction Documents; (vii) there is no action, suit, proceeding, inquiry
or investigation before or by any court, public board or body pending or, to the knowledge of Dermal Diagnostics, threatened against or
affecting Dermal Diagnostics before or by any governmental authority or non-governmental department, commission, board, bureau, agency
or instrumentality or any other person, wherein an unfavorable decision, ruling or finding would adversely affect the validity or enforceability
of, or the authority or ability of Dermal Diagnostics to perform its obligations under, any of the Transaction Documents; (viii) with
respect to any Broker Fees that will or would become due and owing by Dermal Diagnostics to any person or entity as a result of this Agreement
or the transactions contemplated hereby, any such Broker Fees will be made in full compliance with all applicable laws and regulations
and only to a person or entity that is a registered investment adviser or registered broker-dealer; (ix) Investor shall have no obligation
with respect to any Broker Fees or with respect to any claims made by or on behalf of other persons for fees of a type contemplated in
this subsection that may be due in connection with the transactions contemplated hereby and Dermal Diagnostics shall indemnify and hold
harmless each of Investor, Investor’s employees, officers, directors, stockholders, managers, agents, and partners, and their respective
affiliates, from and against all claims, losses, damages, costs (including the costs of preparation and attorneys’ fees) and expenses
suffered in respect of any such claimed or existing Broker Fees; (x) neither Investor nor any of its officers, directors, members, managers,
employees, agents or representatives has made any representations or warranties to Dermal Diagnostics or any of its officers, directors,
employees, agents or representatives except as expressly set forth in the Transaction Documents and, in making its decision to enter into
the transactions contemplated by the Transaction Documents, Dermal Diagnostics is not relying on any representation, warranty, covenant
or promise of Investor or its officers, directors, members, managers, employees, agents or representatives other than as set forth in
the Transaction Documents; (xi) Dermal Diagnostics acknowledges that the State of Utah has a reasonable relationship and sufficient contacts
to the transactions contemplated by the Transaction Documents and any dispute that may arise related thereto such that the laws and venue
of the State of Utah, as set forth more specifically in Section 8.2 below, shall be applicable to the Transaction Documents and the transactions
contemplated therein; (xii) the proceeds from the Note will provide substantial benefits to Dermal Diagnostics; (xiii) Dermal Diagnostics
acknowledges that Investor is not registered as a ‘dealer’ under the 1934 Act; and (xiv) Dermal Diagnostics has performed
due diligence and background research on Investor and its affiliates and has received and reviewed the due diligence packet provided by
Investor. Dermal Diagnostics, being aware of the matters described in subsection (xviii) above, acknowledges and agrees that such matters,
or any similar matters, have no bearing on the transactions contemplated by the Transaction Documents and covenants and agrees it will
not use any such information as a defense to performance of its obligations under the Transaction Documents or in any attempt to avoid,
modify, offset or reduce such obligations. Dermal Diagnostics, being aware of the matters and legal issues described in subsections (xiii)
and (xiv) above, acknowledges and agrees that such matters, or any similar matters, have no bearing on the transactions contemplated by
the Transaction Documents and covenants and agrees it will not use any such information or legal theory as a defense to performance of
its obligations under the Transaction Documents or in any attempt to avoid, modify, reduce, rescind or void such obligations.

    	3 

    	 

    

3.3.
Trial Clinic Representations and Warranties. Trial Clinic represents and warrants to Investor
that as of the Closing Date: (i) Trial Clinic is a corporation duly organized, validly existing and in good standing under the laws of
its state of incorporation and has the requisite corporate power to own its properties and to carry on its business as now being conducted;
(ii) Trial Clinic is duly qualified as a foreign corporation to do business and is in good standing in each jurisdiction where the nature
of the business conducted or property owned by it makes such qualification necessary; (iii) each of the Transaction Documents and the
transactions contemplated hereby and thereby, have been duly and validly authorized by Trial Clinic and all necessary actions have been
taken; (iv) this Agreement, the Note, the Security Agreement and the other Transaction Documents have been duly executed and delivered
by Trial Clinic and constitute the valid and binding obligations of Trial Clinic enforceable in accordance with their terms; (v) the execution
and delivery of the Transaction Documents by Trial Clinic and the consummation by Trial Clinic of the other transactions contemplated
by the Transaction Documents do not and will not conflict with or result in a breach by Trial Clinic of any of the terms or provisions
of, or constitute a default under (a) Trial Clinic’s formation documents or bylaws, each as currently in effect, (b) any indenture,
mortgage, deed of trust, or other material agreement or instrument to which Trial Clinic is a party or by which it or any of its properties
or assets are bound, or (c) any existing applicable law, rule, or regulation or any applicable decree, judgment, or order of any court,
United States federal, state or foreign regulatory body, administrative agency, or other governmental body having jurisdiction over Trial
Clinic or any of Trial Clinic’s properties or assets; (vi) no further authorization, approval or consent of any court, governmental
body, regulatory agency, self-regulatory organization, or stock exchange or market or the stockholders or any lender of Trial Clinic is
required to be obtained by Trial Clinic for the issuance of the Note to Investor or the entering into of the Transaction Documents; (vii)
there is no action, suit, proceeding, inquiry or investigation before or by any court, public board or body pending or, to the knowledge
of Trial Clinic, threatened against or affecting Trial Clinic before or by any governmental authority or non-governmental department,
commission, board, bureau, agency or instrumentality or any other person, wherein an unfavorable decision, ruling or finding would adversely
affect the validity or enforceability of, or the authority or ability of Trial Clinic to perform its obligations under, any of the Transaction
Documents; (viii) with respect to any Broker Fees that will or would become due and owing by Trial Clinic to any person or entity as a
result of this Agreement or the transactions contemplated hereby, any such Broker Fees will be made in full compliance with all applicable
laws and regulations and only to a person or entity that is a registered investment adviser or registered broker-dealer; (ix) Investor
shall have no obligation with respect to any Broker Fees or with respect to any claims made by or on behalf of other persons for fees
of a type contemplated in this subsection that may be due in connection with the transactions contemplated hereby and Trial Clinic shall
indemnify and hold harmless each of Investor, Investor’s employees, officers, directors, stockholders, managers, agents, and partners,
and their respective affiliates, from and against all claims, losses, damages, costs (including the costs of preparation and attorneys’
fees) and expenses suffered in respect of any such claimed or existing Broker Fees; (x) neither Investor nor any of its officers, directors,
members, managers, employees, agents or representatives has made any representations or warranties to Trial Clinic or any of its officers,
directors, employees, agents or representatives except as expressly set forth in the Transaction Documents and, in making its decision
to enter into the transactions contemplated by the Transaction Documents, Trial Clinic is not relying on any representation, warranty,
covenant or promise of Investor or its officers, directors, members, managers, employees, agents or representatives other than as set
forth in the Transaction Documents; (xi) Trial Clinic acknowledges that the State of Utah has a reasonable relationship and sufficient
contacts to the transactions contemplated by the Transaction Documents and any dispute that may arise related thereto such that the laws
and venue of the State of Utah, as set forth more specifically in Section 8.2 below, shall be applicable to the Transaction Documents
and the transactions contemplated therein; (xii) the proceeds from the Note will provide substantial benefits to Trial Clinic; (xiii)
Trial Clinic acknowledges that Investor is not registered as a ‘dealer’ under the 1934 Act; and (xiv) Trial Clinic has performed
due diligence and background research on Investor and its affiliates and has received and reviewed the due diligence packet provided by
Investor. Trial Clinic, being aware of the matters described in subsection (xviii) above, acknowledges and agrees that such matters, or
any similar matters, have no bearing on the transactions contemplated by the Transaction Documents and covenants and agrees it will not
use any such information as a defense to performance of its obligations under the Transaction Documents or in any attempt to avoid, modify,
offset or reduce such obligations. Trial Clinic, being aware of the matters and legal issues described in subsections (xiii) and (xiv)
above, acknowledges and agrees that such matters, or any similar matters, have no bearing on the transactions contemplated by the Transaction
Documents and covenants and agrees it will not use any such information or legal theory as a defense to performance of its obligations
under the Transaction Documents or in any attempt to avoid, modify, reduce, rescind or void such obligations.

    	4 

    	 

    

4.
Company Covenants. Until all of Borrower’s obligations under the Note are paid and performed
in full, or within the timeframes otherwise specifically set forth below, Company will at all times comply with the following covenants:
(i) Company will timely file on the applicable deadline all reports required to be filed with the SEC pursuant to Sections 13 or
15(d) of the 1934 Act, and will take all reasonable action under its control to ensure that adequate current public information with respect
to Company, as required in accordance with Rule 144 of the 1933 Act, is publicly available, and will not terminate its status as an issuer
required to file reports under the 1934 Act even if the 1934 Act or the rules and regulations thereunder would permit such termination;
(ii) the Common Stock shall be listed or quoted for trading on any of (a) NYSE, (b) NASDAQ, (c) OTCQX, or (d) OTCQB; (iii) trading in
Company’s Common Stock will not, for a period of fifteen (15) consecutive days, be suspended, halted, chilled, frozen, reach zero
bid or otherwise cease trading on Company’s principal trading market; (iv) Borrower will not enter into any financing transaction
with John Kirkland or any entity owned by or affiliated with John Kirkland; (v) Company will cause all companies purchased by Company
after the Closing Date until the Note is paid in full to guarantee repayment of the Note using a form of guaranty designated by Investor;
and (vi) Borrower will make any Restricted Issuances (as defined below) without Investor’s prior written consent, which consent
may be granted or withheld in Investor’s sole and absolute discretion. For purposes hereof, the term “Restricted Issuance”
means any issuance or incurrence of any debt (except trade payables) or any Company securities that: (a) have or may have conversion rights
of any kind, contingent, conditional or otherwise, in which the number of shares that may be issued pursuant to such conversion right
varies with the market price of the Common Stock, (b) are or may become convertible into Common Stock (including without limitation convertible
debt, warrants or convertible preferred stock), with a conversion price that varies with the market price of the Common Stock, even if
such security only becomes convertible following an event of default, the passage of time, or another trigger event or condition, or (c)
have a fixed conversion price, exercise price or exchange price that is subject to being reset at some future date at any time after the
initial issuance of such debt or equity security (1) due to a change in the market price of Company’s Common Stock since the date
of the initial issuance or (2) upon the occurrence of specified or contingent events directly or indirectly related to the business of
Company. For avoidance of doubt, the issuance of shares of Common Stock under, pursuant to, in exchange for or in connection with any
contract or instrument, whether convertible or not, is deemed a Restricted Issuance for purposes hereof if the number of shares of Common
Stock to be issued is based upon or related in any way to the market price of the Common Stock, including, but not limited to, Common
Stock issued in connection with a Section 3(a)(9) exchange, a Section 3(a)(10) settlement, or any other similar settlement or exchange.
For the further avoidance of doubt, ATM facilities, shares issued in a public offering, warrants with no exercise price resets or features
that would allow for adjustment to the number of shares exercisable under the warrant will not be considered Restricted Issuances.

5.
Conditions to Borrower’s Obligation to Sell. The obligation of Borrower hereunder to
issue and sell the Note to Investor at the Closing is subject to the satisfaction, on or before the Closing Date, of each of the following
conditions:

5.1.
Investor shall have executed this Agreement and delivered the same to Borrower.

5.2.
Investor shall have delivered the Purchase Price to Borrower in accordance with Section 1.2 above.

6.
Conditions to Investor’s Obligation to Purchase. The obligation of Investor hereunder
to purchase the Note at the Closing is subject to the satisfaction, on or before the Closing Date, of each of the following conditions,
provided that these conditions are for Investor’s sole benefit and may be waived by Investor at any time in its sole discretion:

    	5 

    	 

    

6.1.
Borrower shall have executed this Agreement, the Note and the Security Agreement and delivered the
same to Investor.

6.2.
Company shall have delivered to Investor a fully executed Secretary’s Certificate substantially
in the form attached hereto as Exhibit C evidencing Borrower’s approval of the Transaction Documents.

6.3.
Borrower shall have delivered to Investor fully executed copies of all other Transaction Documents
required to be executed by Borrower herein or therein. 

7.
OFAC; Patriot Act.

7.1.
OFAC Certification. Borrower certifies that (i) it is not acting on behalf of any person,
group, entity, or nation named by any Executive Order or the United States Treasury Department, through its Office of Foreign Assets Control
(“OFAC”) or otherwise, as a terrorist, “Specially Designated Nation”, “Blocked Person”, or
other banned or blocked person, entity, nation, or transaction pursuant to any law, order, rule or regulation that is enforced or administered
by OFAC or another department of the United States government, and (ii) Borrower is not engaged in this transaction on behalf of, or instigating
or facilitating this transaction on behalf of, any such person, group, entity or nation.

7.2.
Foreign Corrupt Practices. Neither Borrower, nor any of its subsidiaries, nor any director,
officer, agent, employee or other person acting on behalf of Borrower or any subsidiary has, in the course of his actions for, or on behalf
of, Borrower, used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political
activity; made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds;
violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or made any bribe, rebate,
payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government official or employee.

7.3.
Patriot Act. Borrower shall not (i) be or become subject at any time to any law, regulation,
or list of any government agency (including, without limitation, the OFAC) that prohibits or limits Investor from making any advance or
extension of credit to Borrower or from otherwise conducting business with Borrower, or (ii) fail to provide documentary and other evidence
of Borrower’s identity as may be requested by Investor at any time to enable Investor to verify Borrower’s identity or to
comply with any applicable law or regulation, including, without limitation, Section 326 of the USA Patriot Act of 2001, 31 U.S.C. Section
5318. Borrower shall comply with all requirements of law relating to money laundering, anti-terrorism, trade embargos and economic sanctions,
now or hereafter in effect. Upon Investor’s request from time to time, Borrower shall certify in writing to Investor that Borrower’s
representations, warranties and obligations under this Section 7.3 remain true and correct and have not been breached. Borrower shall
immediately notify Investor in writing if any of such representations, warranties or covenants are no longer true or have been breached
or if Borrower has a reasonable basis to believe that they may no longer be true or have been breached. In connection with such an event,
Borrower shall comply with all requirements of law and directives of governmental authorities and, at Investor’s request, provide
to Investor copies of all notices, reports and other communications exchanged with, or received from, governmental authorities relating
to such an event. Borrower shall also reimburse Investor any expense incurred by Investor in evaluating the effect of such an event on
the loan secured hereby, in obtaining any necessary license from governmental authorities as may be necessary for Investor to enforce
its rights under the Transaction Documents, and in complying with all requirements of law applicable to Investor as the result of the
existence of such an event and for any penalties or fines imposed upon Investor as a result thereof.

8.
Miscellaneous. The provisions set forth in this Section 8 shall apply to this Agreement, as
well as all other Transaction Documents as if these terms were fully set forth therein; provided, however, that in the event there is
a conflict between any provision set forth in this Section 8 and any provision in any other Transaction Document, the provision in such
other Transaction Document shall govern.

 

    	6 

    	 

    

8.1.
Arbitration of Claims. The parties shall submit all Claims (as defined in Exhibit D)
arising under this Agreement or any other Transaction Document or any other agreement between the parties and their affiliates or any
Claim relating to the relationship of the parties to binding arbitration pursuant to the arbitration provisions set forth in Exhibit
D attached hereto (the “Arbitration Provisions”). For the avoidance of doubt, the parties agree that the injunction
described in Section 8.3 below may be pursued in an arbitration that is separate and apart from any other arbitration regarding all other
Claims arising under the Transaction Documents. The parties hereby acknowledge and agree that the Arbitration Provisions are unconditionally
binding on the parties hereto and are severable from all other provisions of this Agreement. By executing this Agreement, Borrower represents,
warrants and covenants that Borrower has reviewed the Arbitration Provisions carefully, consulted with legal counsel about such provisions
(or waived its right to do so), understands that the Arbitration Provisions are intended to allow for the expeditious and efficient resolution
of any dispute hereunder, agrees to the terms and limitations set forth in the Arbitration Provisions, and that Borrower will not take
a position contrary to the foregoing representations. Borrower acknowledges and agrees that Investor may rely upon the foregoing representations
and covenants of Borrower regarding the Arbitration Provisions.

8.2.
Governing Law; Venue. This Agreement shall be construed and enforced in accordance with, and
all questions concerning the construction, validity, interpretation and performance of this Agreement shall be governed by, the internal
laws of the State of Utah, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Utah
or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Utah. Each party consents
to and expressly agrees that the exclusive venue for arbitration of any dispute arising out of or relating to any Transaction Document
or the relationship of the parties or their affiliates shall be in Salt Lake County, Utah. Without modifying the parties’ obligations
to resolve disputes hereunder pursuant to the Arbitration Provisions, for any litigation arising in connection with any of the Transaction
Documents, each party hereto hereby (i) consents to and expressly submits to the exclusive personal jurisdiction of any state or federal
court sitting in Salt Lake County, Utah, (ii) expressly submits to the exclusive venue of any such court for the purposes hereof, and
(iii) waives any claim of improper venue and any claim or objection that such courts are an inconvenient forum or any other claim, defense
or objection to the bringing of any such proceeding in such jurisdiction or to any claim that such venue of the suit, action or proceeding
is improper. Finally, Borrower covenants and agrees to name Investor as a party in interest in, and provide written notice to Investor
in accordance with Section 8.11 below prior to bringing or filing any action (including without limitation any filing or action against
any person or entity that is not a party to this Agreement) that is related in any way to the Transaction Documents or any transaction
contemplated herein or therein, and further agrees to timely name Investor as a party to any such action. Borrower acknowledges that the
governing law and venue provisions set forth in this Section 8.2 are material terms to induce Investor to enter into the Transaction Documents
and that but for Borrower’s agreements set forth in this Section 8.2 Investor would not have entered into the Transaction Documents.

8.3.
Specific Performance. Borrower acknowledges and agrees that Investor may suffer irreparable
harm in the event that Borrower fails to perform any material provision of this Agreement or any of the other Transaction Documents in
accordance with its specific terms. It is accordingly agreed that Investor shall be entitled to one or more injunctions to prevent or
cure breaches of the provisions of this Agreement or such other Transaction Document and to enforce specifically the terms and provisions
hereof or thereof, this being in addition to any other remedy to which the Investor may be entitled under the Transaction Documents, at
law or in equity. Borrower specifically agrees that following an Event of Default (as defined in the Note) under the Note, Investor shall
have the right to seek and receive injunctive relief from a court or an arbitrator prohibiting Borrower from issuing any of its common
or preferred stock to any party unless the Note is being paid in full simultaneously with such issuance. Borrower specifically acknowledges
that Investor’s right to obtain specific performance constitutes bargained for leverage and that the loss of such leverage would
result in irreparable harm to Investor. For the avoidance of doubt, in the event Investor seeks to obtain an injunction from a court or
an arbitrator against Borrower or specific performance of any provision of any Transaction Document, such action shall not be a waiver
of any right of Investor under any Transaction Document, at law, or in equity, including without limitation its rights to arbitrate any
Claim pursuant to the terms of the Transaction Documents, nor shall Investor’s pursuit of an injunction prevent Investor, under
the doctrines of claim preclusion, issues preclusion, res judicata or other similar legal doctrines, from pursuing other Claims in the
future in a separate arbitration.

8.4.
Counterparts. Each Transaction Document may be executed in any number of counterparts, each
of which shall be deemed an original, but all of which together shall constitute one instrument. The parties hereto confirm that any electronic
copy of another party’s executed counterpart of a Transaction Document (or such party’s signature page thereof) will be deemed
to be an executed original thereof.

 

    	7 

    	 

    

8.5.
Document Imaging. Investor shall be entitled, in its sole discretion, to image or make copies
of all or any selection of the agreements, instruments, documents, and items and records governing, arising from or relating to any of
Borrower’s loans, including, without limitation, this Agreement and the other Transaction Documents, and Investor may destroy or
archive the paper originals. The parties hereto (i) waive any right to insist or require that Investor produce paper originals, (ii)
agree that such images shall be accorded the same force and effect as the paper originals, (iii) agree that Investor is entitled to use
such images in lieu of destroyed or archived originals for any purpose, including as admissible evidence in any demand, presentment or
other proceedings, and (iv) further agree that any executed facsimile (faxed), scanned, emailed, or other imaged copy of this Agreement
or any other Transaction Document shall be deemed to be of the same force and effect as the original manually executed document.

8.6.
Headings. The headings of this Agreement are for convenience of reference only and shall not
form part of, or affect the interpretation of, this Agreement.

8.7.
Severability. In the event that any provision of this Agreement is invalid or unenforceable
under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent that it may conflict therewith
and shall be deemed modified to conform to such statute or rule of law. Any provision hereof which may prove invalid or unenforceable
under any law shall not affect the validity or enforceability of any other provision hereof.

8.8.
Entire Agreement. This Agreement, together with the other Transaction Documents, contains
the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein
or therein, neither Borrower nor Investor makes any representation, warranty, covenant or undertaking with respect to such matters. For
the avoidance of doubt, all prior term sheets or other documents between Borrower and Investor, or any affiliate thereof, related to the
transactions contemplated by the Transaction Documents (collectively, “Prior Agreements”), that may have been entered
into between Borrower and Investor, or any affiliate thereof, are hereby null and void and deemed to be replaced in their entirety by
the Transaction Documents. To the extent there is a conflict between any term set forth in any Prior Agreement and the term(s) of the
Transaction Documents, the Transaction Documents shall govern.

8.9.
No Reliance. Borrower acknowledges and agrees that neither Investor nor any of its officers,
directors, members, managers, representatives or agents has made any representations or warranties to Borrower or any of its officers,
directors, representatives, agents or employees except as expressly set forth in the Transaction Documents and, in making its decision
to enter into the transactions contemplated by the Transaction Documents, Borrower is not relying on any representation, warranty, covenant
or promise of Investor or its officers, directors, members, managers, agents or representatives other than as set forth in the Transaction
Documents.

8.10.
Amendments. No provision of this Agreement may be waived or amended other than by an instrument
in writing signed by both parties hereto.

8.11.
Notices. Any notice required or permitted hereunder shall be given in writing (unless otherwise
specified herein) and shall be deemed effectively given on the earliest of: (i) the date delivered, if delivered by personal delivery
as against written receipt therefor or by email to an executive officer, or by facsimile (with successful transmission confirmation),
(ii) the earlier of the date delivered or the third business day after deposit, postage prepaid, in the United States Postal Service by
certified mail, or (iii) the earlier of the date delivered or the third business day after mailing by express courier, with delivery costs
and fees prepaid, in each case, addressed to each of the other parties thereunto entitled at the following addresses (or at such other
addresses as such party may designate by five (5) calendar days’ advance written notice similarly given to each of the other parties
hereto):

If to Borrower:

 

Nemaura Medical Inc.

Attn: Dewan Chowdhury

57 West 57th Street

Manhattan, New York 10019

 

 

    	8 

    	 

    

With a copy to (which copy shall not constitute notice):

 

Anthony L.G., PLLC

Attn: Laura Anthony

625 N. Flagler Drive, Suite 600

West Palm Beach, FL 33401

 

If to Investor:

 

Streeterville Capital, LLC

Attn: John Fife

303 East Wacker Drive, Suite 1040

Chicago, Illinois 60601

 

With a copy to (which copy shall not constitute notice):

 

Hansen Black Anderson Ashcraft PLLC

Attn: Jonathan K. Hansen

3051 West Maple Loop Drive, Suite 325

Lehi, Utah 84043

 

8.12.
Successors and Assigns. This Agreement or any of the severable rights and obligations inuring
to the benefit of or to be performed by Investor hereunder may be assigned by Investor to its affiliates, in whole or in part, without
the need to obtain Borrower’s consent thereto. Except as set forth above, neither Investor nor Borrower may assign its rights or
obligations under this Agreement or delegate its duties hereunder without the prior written consent of the other party.

8.13.
Survival. The representations and warranties of the parties and the agreements and covenants
set forth in this Agreement shall survive the Closing hereunder notwithstanding any due diligence investigation conducted by or on behalf
of each party. Each party agrees to indemnify and hold harmless the other and all its respective officers, directors, employees, attorneys,
and agents for loss or damage arising as a result of or related to any breach or alleged breach by the other party of any of its representations,
warranties and covenants set forth in this Agreement or any of its covenants and obligations under this Agreement, including advancement
of expenses as they are incurred.

8.14.
Further Assurances. Each party shall do and perform, or cause to be done and performed, all
such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as the
other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation
of the transactions contemplated hereby.

8.15.
Rights and Remedies Cumulative. All rights, remedies, and powers conferred in this Agreement
and the Transaction Documents are cumulative and not exclusive of any other rights or remedies, and shall be in addition to every other
right, power, and remedy that any party may have, whether specifically granted in this Agreement or any other Transaction Document, or
existing at law, in equity, or by statute, and any and all such rights and remedies may be exercised from time to time and as often and
in such order as such party may deem expedient.

 

    	9 

    	 

    

8.16.
Attorneys’ Fees and Cost of Collection. In the event any suit, action or arbitration
is filed by either party against the other to interpret or enforce any of the Transaction Documents, the unsuccessful party to such action
agrees to pay to the prevailing party all costs and expenses, including attorneys’ fees incurred therein, including the same with
respect to an appeal. The “prevailing party” shall be the party in whose favor a judgment is entered, regardless of whether
judgment is entered on all claims asserted by such party and regardless of the amount of the judgment; or where, due to the assertion
of counterclaims, judgments are entered in favor of and against both parties, then the arbitrator shall determine the “prevailing
party” by taking into account the relative dollar amounts of the judgments or, if the judgments involve nonmonetary relief, the
relative importance and value of such relief. Nothing herein shall restrict or impair an arbitrator’s or a court’s power to
award fees and expenses for frivolous or bad faith pleading. If (i) the Note is placed in the hands of an attorney for collection
or enforcement prior to commencing arbitration or legal proceedings, or is collected or enforced through any arbitration or legal proceeding,
or Investor otherwise takes action to collect amounts due under the Note or to enforce the provisions of the Note, or (ii) there
occurs any bankruptcy, reorganization, receivership of Borrower or other proceedings affecting Borrower’s creditors’ rights
and involving a claim under the Note; then Borrower shall pay the costs incurred by Investor for such collection, enforcement or action
or in connection with such bankruptcy, reorganization, receivership or other proceeding, including, without limitation, attorneys’
fees, expenses, deposition costs, and disbursements.

8.17.
Waiver. No waiver of any provision of this Agreement shall be effective unless it is in the
form of a writing signed by the party granting the waiver. No waiver of any provision or consent to any prohibited action shall constitute
a waiver of any other provision or consent to any other prohibited action, whether or not similar. No waiver or consent shall constitute
a continuing waiver or consent or commit a party to provide a waiver or consent in the future except to the extent specifically set forth
in writing.

8.18.
Waiver of Jury Trial. EACH PARTY TO THIS AGREEMENT IRREVOCABLY WAIVES ANY AND ALL RIGHTS SUCH
PARTY MAY HAVE TO DEMAND THAT ANY ACTION, PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR IN ANY WAY RELATED TO THIS AGREEMENT, ANY OTHER
TRANSACTION DOCUMENT, OR THE RELATIONSHIPS OF THE PARTIES HERETO BE TRIED BY JURY. THIS WAIVER EXTENDS TO ANY AND ALL RIGHTS TO DEMAND
A TRIAL BY JURY ARISING UNDER COMMON LAW OR ANY APPLICABLE STATUTE, LAW, RULE OR REGULATION. FURTHER, EACH PARTY HERETO ACKNOWLEDGES THAT
SUCH PARTY IS KNOWINGLY AND VOLUNTARILY WAIVING SUCH PARTY’S RIGHT TO DEMAND TRIAL BY JURY. 

8.19.
Time is of the Essence. Time is expressly made of the essence with respect to each and every
provision of this Agreement and the other Transaction Documents.

8.20.
Voluntary Agreement. Borrower has carefully read this Agreement and each of the other Transaction
Documents and has asked any questions needed for Borrower to understand the terms, consequences and binding effect of this Agreement and
each of the other Transaction Documents and fully understand them. Borrower has had the opportunity to seek the advice of an attorney
of Borrower’s choosing, or has waived the right to do so, and is executing this Agreement and each of the other Transaction Documents
voluntarily and without any duress or undue influence by Investor or anyone else.

8.21.
Joint and Several Obligations. To the extent applicable, any references in this Agreement
and each of the other Transaction Documents to Borrower refer to each person or entity constituting Borrower jointly and severally, and
all promises, agreements, covenants, waivers, consents, representations, warranties, and other provisions in this Agreement are made by
and are binding upon each such undersigned person or entity, jointly and severally.

[Remainder of page intentionally left blank; signature
page follows]

 

 

    	10 

    	 

    

IN WITNESS WHEREOF, the
undersigned Investor and Borrower have caused this Agreement to be duly executed as of the date first above written.

 

INVESTOR:

 

Streeterville
Capital, LLC

 

 

By: /s/ John M. Fife

John M. Fife, President 

 

BORROWER:

 

Nemaura
Medical Inc.

 

 

By:/s/ Dewan F.H. Chowdhury

Name: Dewan F.H. Chowdhury

Title: CEO

 

Dermal
Diagnostics Limited

 

 

By:/s/ Dewan F.H. Chowdhury

Name: Dewan F.H. Chowdhury

Title: Director

 

 

Trial
Clinic Limited

 

 

By:/s/ Dewan F.H. Chowdhury

Name: Dewan F.H. Chowdhury

Title: Director

 

 

 

ATTACHED EXHIBITS:

 

		Exhibit	A                     
Note

		Exhibit	B                     
Security Agreement

		Exhibit	C                     
Secretary’s Certificate

		Exhibit	D                     
Arbitration Provisions

 

 

    	 

    	 

    

Exhibit
D

 

ARBITRATION PROVISIONS

 

1.Dispute
Resolution. For purposes of this Exhibit D, the term “Claims” means any disputes, claims, demands, causes
of action, requests for injunctive relief, requests for specific performance, liabilities, damages, losses, or controversies whatsoever
arising from, related to, or connected with the transactions contemplated in the Transaction Documents and any communications between
the parties related thereto, including without limitation any claims of mutual mistake, mistake, fraud, misrepresentation, failure of
formation, failure of consideration, promissory estoppel, unconscionability, failure of condition precedent, rescission, and any statutory
claims, tort claims, contract claims, or claims to void, invalidate or terminate the Agreement (or these Arbitration Provisions (defined
below)) or any of the other Transaction Documents. The parties to this Agreement (the “parties”) hereby agree that
the Claims may be arbitrated in one or more Arbitrations pursuant to these Arbitration Provisions (one for an injunction or injunctions
and a separate one for all other Claims). The parties hereby agree that the arbitration provisions set forth in this Exhibit D
(“Arbitration Provisions”) are binding on each of them. As a result, any attempt to rescind the Agreement (or these
Arbitration Provisions) or any other Transaction Document) or declare the Agreement (or these Arbitration Provisions) or any other Transaction
Document invalid or unenforceable pursuant to Section 29 of the 1934 Act or for any other reason is subject to these Arbitration Provisions.
These Arbitration Provisions shall also survive any termination or expiration of the Agreement Any capitalized term not defined in these
Arbitration Provisions shall have the meaning set forth in the Agreement.

2.Arbitration.
Except as otherwise provided herein, all Claims must be submitted to arbitration (“Arbitration”) to be conducted exclusively
in Salt Lake County, Utah and pursuant to the terms set forth in these Arbitration Provisions. Subject to the arbitration appeal right
provided for in Paragraph 5 below (the “Appeal Right”), the parties agree that the award of the arbitrator rendered
pursuant to Paragraph 4 below (the “Arbitration Award”) shall be (a) final and binding upon the parties, (b) the sole
and exclusive remedy between them regarding any Claims, counterclaims, issues, or accountings presented or pleaded to the arbitrator,
and (c) promptly payable in United States dollars free of any tax, deduction or offset (with respect to monetary awards). Subject to the
Appeal Right, any costs or fees, including without limitation attorneys’ fees, incurred in connection with or incident to enforcing
the Arbitration Award shall, to the maximum extent permitted by law, be charged against the party resisting such enforcement. The Arbitration
Award shall include default interest (as defined or otherwise provided for in the Note, “Default Interest”) (with respect
to monetary awards) at the rate specified in the Note for Default Interest both before and after the Arbitration Award. Judgment upon
the Arbitration Award will be entered and enforced by any state or federal court sitting in Salt Lake County, Utah.

3.The
Arbitration Act. The parties hereby incorporate herein the provisions and procedures set forth in the Utah Uniform Arbitration Act,
U.C.A. § 78B-11-101 et seq. (as amended or superseded from time to time, the “Arbitration Act”). Notwithstanding
the foregoing, pursuant to, and to the maximum extent permitted by, Section 105 of the Arbitration Act, in the event of conflict or variation
between the terms of these Arbitration Provisions and the provisions of the Arbitration Act, the terms of these Arbitration Provisions
shall control and the parties hereby waive or otherwise agree to vary the effect of all requirements of the Arbitration Act that may conflict
with or vary from these Arbitration Provisions.

4.Arbitration
Proceedings. Arbitration between the parties will be subject to the following:

4.1Initiation
of Arbitration. Pursuant to Section 110 of the Arbitration Act, the parties agree that a party may initiate Arbitration by giving
written notice to the other party (“Arbitration Notice”) in the same manner that notice is permitted under Section
8.11 of the Agreement; provided, however, that the Arbitration Notice may not be given by email or fax. Arbitration will be deemed
initiated as of the date that the Arbitration Notice is deemed delivered to such other party under Section 8.11 of the Agreement (the
“Service Date”). After the Service Date, information may be delivered, and notices may be given, by email or fax pursuant
to Section 8.11 of the Agreement or any other method permitted thereunder. The Arbitration Notice must describe the nature of the controversy,
the remedies sought, and the election to commence Arbitration proceedings. All Claims in the Arbitration Notice must be pleaded consistent
with the Utah Rules of Civil Procedure.

 

    	Page 1 

    	 

    

4.2Selection
and Payment of Arbitrator.

(a) Within ten (10)
calendar days after the Service Date, Investor shall select and submit to Company the names of three (3) arbitrators that are designated
as “neutrals” or qualified arbitrators by Utah ADR Services (http://www.utahadrservices.com) (such three (3) designated persons
hereunder are referred to herein as the “Proposed Arbitrators”). For the avoidance of doubt, each Proposed Arbitrator
must be qualified as a “neutral” with Utah ADR Services. Within five (5) calendar days after Investor has submitted to Company
the names of the Proposed Arbitrators, Company must select, by written notice to Investor, one (1) of the Proposed Arbitrators to act
as the arbitrator for the parties under these Arbitration Provisions. If Company fails to select one of the Proposed Arbitrators in writing
within such 5-day period, then Investor may select the arbitrator from the Proposed Arbitrators by providing written notice of such selection
to Company.

(b) If Investor fails
to submit to Company the Proposed Arbitrators within ten (10) calendar days after the Service Date pursuant to subparagraph (a) above,
then Company may at any time prior to Investor so designating the Proposed Arbitrators, identify the names of three (3) arbitrators that
are designated as “neutrals” or qualified arbitrators by Utah ADR Service by written notice to Investor. Investor may then,
within five (5) calendar days after Company has submitted notice of its Proposed Arbitrators to Investor, select, by written notice to
Company, one (1) of the Proposed Arbitrators to act as the arbitrator for the parties under these Arbitration Provisions. If Investor
fails to select in writing and within such 5-day period one (1) of the three (3) Proposed Arbitrators selected by Company, then Company
may select the arbitrator from its three (3) previously selected Proposed Arbitrators by providing written notice of such selection to
Investor.

(c) If a Proposed Arbitrator
chosen to serve as arbitrator declines or is otherwise unable to serve as arbitrator, then the party that selected such Proposed Arbitrator
may select one (1) of the other three (3) Proposed Arbitrators within three (3) calendar days of the date the chosen Proposed Arbitrator
declines or notifies the parties he or she is unable to serve as arbitrator. If all three (3) Proposed Arbitrators decline or are otherwise
unable to serve as arbitrator, then the arbitrator selection process shall begin again in accordance with this Paragraph 4.2.

(d) The date that the
Proposed Arbitrator selected pursuant to this Paragraph 4.2 agrees in writing (including via email) delivered to both parties to serve
as the arbitrator hereunder is referred to herein as the “Arbitration Commencement Date”. If an arbitrator resigns
or is unable to act during the Arbitration, a replacement arbitrator shall be chosen in accordance with this Paragraph 4.2 to continue
the Arbitration. If Utah ADR Services ceases to exist or to provide a list of neutrals and there is no successor thereto, then the arbitrator
shall be selected under the then prevailing rules of the American Arbitration Association.

(e) Subject to Paragraph
4.10 below, the cost of the arbitrator must be paid equally by both parties. Subject to Paragraph 4.10 below, if one party refuses or
fails to pay its portion of the arbitrator fee, then the other party can advance such unpaid amount (subject to the accrual of Default
Interest thereupon), with such amount being added to or subtracted from, as applicable, the Arbitration Award.

4.3Applicability
of Certain Utah Rules. The parties agree that the Arbitration shall be conducted generally in accordance with the Utah Rules of Civil
Procedure and the Utah Rules of Evidence. More specifically, the Utah Rules of Civil Procedure shall apply, without limitation, to the
filing of any pleadings, motions or memoranda, the conducting of discovery, and the taking of any depositions. The Utah Rules of Evidence
shall apply to any hearings, whether telephonic or in person, held by the arbitrator. Notwithstanding the foregoing, it is the parties’
intent that the incorporation of such rules will in no event supersede these Arbitration Provisions. In the event of any conflict between
the Utah Rules of Civil Procedure or the Utah Rules of Evidence and these Arbitration Provisions, these Arbitration Provisions shall control.

4.4Answer
and Default. An answer and any counterclaims to the Arbitration Notice shall be required to be delivered to the party initiating the
Arbitration within twenty (20) calendar days after the Arbitration Commencement Date. If an answer is not delivered by the required deadline,
the arbitrator must provide written notice to the defaulting party stating that the arbitrator will enter a default award against such
party if such party does not file an answer within five (5) calendar days of receipt of such notice. If an answer is not filed within
the five (5) day extension period, the arbitrator must render a default award, consistent with the relief requested in the Arbitration
Notice, against a party that fails to submit an answer within such time period.

4.5Related
Litigation. The party that delivers the Arbitration Notice to the other party shall have the option to also commence concurrent legal
proceedings with any state or federal court sitting in Salt Lake County, Utah (“Litigation Proceedings”), subject to
the following: (a) the complaint in the Litigation Proceedings is to be substantially similar to the claims set forth in the Arbitration
Notice, provided that an additional cause of action to compel arbitration will also be included therein, (b) so long as the other party
files an answer to the complaint in the Litigation Proceedings and an answer to the Arbitration Notice, the Litigation Proceedings will
be stayed pending an Arbitration Award (or Appeal Panel Award (defined below), as applicable) hereunder, (c) if the other party fails
to file an answer in the Litigation Proceedings or an answer in the Arbitration proceedings, then the party initiating Arbitration shall
be entitled to a default judgment consistent with the relief requested, to be entered in the Litigation Proceedings, and (d) any legal
or procedural issue arising under the Arbitration Act that requires a decision of a court of competent jurisdiction may be determined
in the Litigation Proceedings. Any award of the arbitrator (or of the Appeal Panel (defined below)) may be entered in such Litigation
Proceedings pursuant to the Arbitration Act.

 

    	Page 2 

    	 

    

4.6Discovery.
Pursuant to Section 118(8) of the Arbitration Act, the parties agree that discovery shall be conducted as follows:

(a) Written discovery
will only be allowed if the likely benefits of the proposed written discovery outweigh the burden or expense thereof, and the written
discovery sought is likely to reveal information that will satisfy a specific element of a claim or defense already pleaded in the Arbitration.
The party seeking written discovery shall always have the burden of showing that all of the standards and limitations set forth in these
Arbitration Provisions are satisfied. The scope of discovery in the Arbitration proceedings shall also be limited as follows:

(i)To
facts directly connected with the transactions contemplated by the Agreement.

(ii)To
facts and information that cannot be obtained from another source or in another manner that is more convenient, less burdensome or less
expensive than in the manner requested.

(b) No party shall
be allowed (i) more than fifteen (15) interrogatories (including discrete subparts), (ii) more than fifteen (15) requests for admission
(including discrete subparts), (iii) more than ten (10) document requests (including discrete subparts), or (iv) more than three (3) depositions
(excluding expert depositions) for a maximum of seven (7) hours per deposition. The costs associated with depositions will be borne by
the party taking the deposition. The party defending the deposition will submit a notice to the party taking the deposition of the estimated
attorneys’ fees that such party expects to incur in connection with defending the deposition. If the party defending the deposition
fails to submit an estimate of attorneys’ fees within five (5) calendar days of its receipt of a deposition notice, then such party
shall be deemed to have waived its right to the estimated attorneys’ fees. The party taking the deposition must pay the party defending
the deposition the estimated attorneys’ fees prior to taking the deposition, unless such obligation is deemed to be waived as set
forth in the immediately preceding sentence. If the party taking the deposition believes that the estimated attorneys’ fees are
unreasonable, such party may submit the issue to the arbitrator for a decision. All depositions will be taken in Utah.

(c) All discovery requests
(including document production requests included in deposition notices) must be submitted in writing to the arbitrator and the other party.
The party submitting the written discovery requests must include with such discovery requests a detailed explanation of how the proposed
discovery requests satisfy the requirements of these Arbitration Provisions and the Utah Rules of Civil Procedure. The receiving party
will then be allowed, within five (5) calendar days of receiving the proposed discovery requests, to submit to the arbitrator an estimate
of the attorneys’ fees and costs associated with responding to such written discovery requests and a written challenge to each applicable
discovery request. After receipt of an estimate of attorneys’ fees and costs and/or challenge(s) to one or more discovery requests,
consistent with subparagraph (c) above, the arbitrator will within three (3) calendar days make a finding as to the likely attorneys’
fees and costs associated with responding to the discovery requests and issue an order that (i) requires the requesting party to prepay
the attorneys’ fees and costs associated with responding to the discovery requests, and (ii) requires the responding party to respond
to the discovery requests as limited by the arbitrator within twenty-five (25) calendar days of the arbitrator’s finding with respect
to such discovery requests. If a party entitled to submit an estimate of attorneys’ fees and costs and/or a challenge to discovery
requests fails to do so within such 5-day period, the arbitrator will make a finding that (A) there are no attorneys’ fees or costs
associated with responding to such discovery requests, and (B) the responding party must respond to such discovery requests (as may be
limited by the arbitrator) within twenty-five (25) calendar days of the arbitrator’s finding with respect to such discovery requests.
Any party submitting any written discovery requests, including without limitation interrogatories, requests for production subpoenas to
a party or a third party, or requests for admissions, must prepay the estimated attorneys’ fees and costs, before the responding
party has any obligation to produce or respond to the same, unless such obligation is deemed waived as set forth above.

(d) In order to allow
a written discovery request, the arbitrator must find that the discovery request satisfies the standards set forth in these Arbitration
Provisions and the Utah Rules of Civil Procedure. The arbitrator must strictly enforce these standards. If a discovery request does not
satisfy any of the standards set forth in these Arbitration Provisions or the Utah Rules of Civil Procedure, the arbitrator may modify
such discovery request to satisfy the applicable standards, or strike such discovery request in whole or in part.

 

    	Page 3 

    	 

    

(e) Each party may
submit expert reports (and rebuttals thereto), provided that such reports must be submitted within sixty (60) days of the Arbitration
Commencement Date. Each party will be allowed a maximum of two (2) experts. Expert reports must contain the following: (i) a complete
statement of all opinions the expert will offer at trial and the basis and reasons for them; (ii) the expert’s name and qualifications,
including a list of all the expert’s publications within the preceding ten (10) years, and a list of any other cases in which the
expert has testified at trial or in a deposition or prepared a report within the preceding ten (10) years; and (iii) the compensation
to be paid for the expert’s report and testimony. The parties are entitled to depose any other party’s expert witness one
(1) time for no more than four (4) hours. An expert may not testify in a party’s case-in-chief concerning any matter not fairly
disclosed in the expert report.

4.6Dispositive
Motions. Each party shall have the right to submit dispositive motions pursuant Rule 12 or Rule 56 of the Utah Rules of Civil Procedure
(a “Dispositive Motion”). The party submitting the Dispositive Motion may, but is not required to, deliver to the arbitrator
and to the other party a memorandum in support (the “Memorandum in Support”) of the Dispositive Motion. Within seven
(7) calendar days of delivery of the Memorandum in Support, the other party shall deliver to the arbitrator and to the other party a memorandum
in opposition to the Memorandum in Support (the “Memorandum in Opposition”). Within seven (7) calendar days of delivery
of the Memorandum in Opposition, as applicable, the party that submitted the Memorandum in Support shall deliver to the arbitrator and
to the other party a reply memorandum to the Memorandum in Opposition (“Reply Memorandum”). If the applicable party
shall fail to deliver the Memorandum in Opposition as required above, or if the other party fails to deliver the Reply Memorandum as required
above, then the applicable party shall lose its right to so deliver the same, and the Dispositive Motion shall proceed regardless.

4.7Confidentiality.
All information disclosed by either party (or such party’s agents) during the Arbitration process (including without limitation
information disclosed during the discovery process or any Appeal (defined below)) shall be considered confidential in nature. Each party
agrees not to disclose any confidential information received from the other party (or its agents) during the Arbitration process (including
without limitation during the discovery process or any Appeal) unless (a) prior to or after the time of disclosure such information becomes
public knowledge or part of the public domain, not as a result of any inaction or action of the receiving party or its agents, (b) such
information is required by a court order, subpoena or similar legal duress to be disclosed if such receiving party has notified the other
party thereof in writing and given it a reasonable opportunity to obtain a protective order from a court of competent jurisdiction prior
to disclosure, or (c) such information is disclosed to the receiving party’s agents, representatives and legal counsel on a need
to know basis who each agree in writing not to disclose such information to any third party. Pursuant to Section 118(5) of the Arbitration
Act, the arbitrator is hereby authorized and directed to issue a protective order to prevent the disclosure of privileged information
and confidential information upon the written request of either party.

4.8Authorization;
Timing; Scheduling Order. Subject to all other portions of these Arbitration Provisions, the parties hereby authorize and direct the
arbitrator to take such actions and make such rulings as may be necessary to carry out the parties’ intent for the Arbitration proceedings
to be efficient and expeditious. Pursuant to Section 120 of the Arbitration Act, the parties hereby agree that an Arbitration Award must
be made within one hundred twenty (120) calendar days after the Arbitration Commencement Date. The arbitrator is hereby authorized and
directed to hold a scheduling conference within ten (10) calendar days after the Arbitration Commencement Date in order to establish a
scheduling order with various binding deadlines for discovery, expert testimony, and the submission of documents by the parties to enable
the arbitrator to render a decision prior to the end of such 120-day period.

4.9Relief.
The arbitrator shall have the right to award or include in the Arbitration Award (or in a preliminary ruling) any relief which the arbitrator
deems proper under the circumstances, including, without limitation, specific performance and injunctive relief, provided that the arbitrator
may not award exemplary or punitive damages.

4.10Fees
and Costs. As part of the Arbitration Award, the arbitrator is hereby directed to require the losing party (the party being awarded
the least amount of money by the arbitrator, which, for the avoidance of doubt, shall be determined without regard to any statutory fines,
penalties, fees, or other charges awarded to any party) to (a) pay the full amount of any unpaid costs and fees of the Arbitration, and
(b) reimburse the prevailing party for all reasonable attorneys’ fees, arbitrator costs and fees, deposition costs, other discovery
costs, and other expenses, costs or fees paid or otherwise incurred by the prevailing party in connection with the Arbitration.

5.Arbitration
Appeal.

5.1Initiation
of Appeal. Following the entry of the Arbitration Award, either party (the “Appellant”) shall have a period of
thirty (30) calendar days in which to notify the other party (the “Appellee”), in writing, that the Appellant elects
to appeal (the “Appeal”) the Arbitration Award (such notice, an “Appeal Notice”) to a panel of arbitrators
as provided in Paragraph 5.2 below. The date the Appellant delivers an Appeal Notice to the Appellee is referred to herein as the “Appeal
Date”. The Appeal Notice must be delivered to the Appellee in accordance with the provisions of Paragraph 4.1 above with respect
to delivery of an Arbitration Notice. In addition, together with delivery of the Appeal Notice to the Appellee, the Appellant must also
pay for (and provide proof of such payment to the Appellee together with delivery of the Appeal Notice) a bond in the amount of 110% of
the sum the Appellant owes to the Appellee as a result of the Arbitration Award the Appellant is appealing. In the event an Appellant
delivers an Appeal Notice to the Appellee (together with proof of payment of the applicable bond) in compliance with the provisions of
this Paragraph 5.1, the Appeal will occur as a matter of right and, except as specifically set forth herein, will not be further conditioned.
In the event a party does not deliver an Appeal Notice (along with proof of payment of the applicable bond) to the other party within
the deadline prescribed in this Paragraph 5.1, such party shall lose its right to appeal the Arbitration Award. If no party delivers an
Appeal Notice (along with proof of payment of the applicable bond) to the other party within the deadline described in this Paragraph
5.1, the Arbitration Award shall be final. The parties acknowledge and agree that any Appeal shall be deemed part of the parties’
agreement to arbitrate for purposes of these Arbitration Provisions and the Arbitration Act.

 

    	Page 4 

    	 

    

5.2Selection
and Payment of Appeal Panel. In the event an Appellant delivers an Appeal Notice to the Appellee (together with proof of payment of
the applicable bond) in compliance with the provisions of Paragraph 5.1 above, the Appeal will be heard by a three (3) person arbitration
panel (the “Appeal Panel”).

(a) Within ten
(10) calendar days after the Appeal Date, the Appellee shall select and submit to the Appellant the names of five (5) arbitrators that
are designated as “neutrals” or qualified arbitrators by Utah ADR Services (http://www.utahadrservices.com) (such five (5)
designated persons hereunder are referred to herein as the “Proposed Appeal Arbitrators”). For the avoidance of doubt,
each Proposed Appeal Arbitrator must be qualified as a “neutral” with Utah ADR Services, and shall not be the arbitrator who
rendered the Arbitration Award being appealed (the “Original Arbitrator”). Within five (5) calendar days after the
Appellee has submitted to the Appellant the names of the Proposed Appeal Arbitrators, the Appellant must select, by written notice to
the Appellee, three (3) of the Proposed Appeal Arbitrators to act as the members of the Appeal Panel. If the Appellant fails to select
three (3) of the Proposed Appeal Arbitrators in writing within such 5-day period, then the Appellee may select such three (3) arbitrators
from the Proposed Appeal Arbitrators by providing written notice of such selection to the Appellant.

(b) If the Appellee
fails to submit to the Appellant the names of the Proposed Appeal Arbitrators within ten (10) calendar days after the Appeal Date pursuant
to subparagraph (a) above, then the Appellant may at any time prior to the Appellee so designating the Proposed Appeal Arbitrators, identify
the names of five (5) arbitrators that are designated as “neutrals” or qualified arbitrators by Utah ADR Service (none of
whom may be the Original Arbitrator) by written notice to the Appellee. The Appellee may then, within five (5) calendar days after the
Appellant has submitted notice of its selected arbitrators to the Appellee, select, by written notice to the Appellant, three (3) of such
selected arbitrators to serve on the Appeal Panel. If the Appellee fails to select in writing within such 5-day period three (3) of the
arbitrators selected by the Appellant to serve as the members of the Appeal Panel, then the Appellant may select the three (3) members
of the Appeal Panel from the Appellant’s list of five (5) arbitrators by providing written notice of such selection to the Appellee.

(c) If a selected
Proposed Appeal Arbitrator declines or is otherwise unable to serve, then the party that selected such Proposed Appeal Arbitrator may
select one (1) of the other five (5) designated Proposed Appeal Arbitrators within three (3) calendar days of the date a chosen Proposed
Appeal Arbitrator declines or notifies the parties he or she is unable to serve as an arbitrator. If at least three (3) of the five (5)
designated Proposed Appeal Arbitrators decline or are otherwise unable to serve, then the Proposed Appeal Arbitrator selection process
shall begin again in accordance with this Paragraph 5.2; provided, however, that any Proposed Appeal Arbitrators who have already
agreed to serve shall remain on the Appeal Panel.

(d)The date that
all three (3) Proposed Appeal Arbitrators selected pursuant to this Paragraph 5.2 agree in writing (including via email) delivered to
both the Appellant and the Appellee to serve as members of the Appeal Panel hereunder is referred to herein as the “Appeal Commencement
Date”. No later than five (5) calendar days after the Appeal Commencement Date, the Appellee shall designate in writing (including
via email) to the Appellant and the Appeal Panel the name of one (1) of the three (3) members of the Appeal Panel to serve as the lead
arbitrator in the Appeal proceedings. Each member of the Appeal Panel shall be deemed an arbitrator for purposes of these Arbitration
Provisions and the Arbitration Act, provided that, in conducting the Appeal, the Appeal Panel may only act or make determinations upon
the approval or vote of no less than the majority vote of its members, as announced or communicated by the lead arbitrator on the Appeal
Panel. If an arbitrator on the Appeal Panel ceases or is unable to act during the Appeal proceedings,
a replacement arbitrator shall be chosen in accordance with Paragraph 5.2 above to continue the Appeal as a member of the Appeal Panel.
If Utah ADR Services ceases to exist or to provide a list of neutrals, then the arbitrators for the Appeal Panel shall be selected
under the then prevailing rules of the American Arbitration Association.

(d) Subject to
Paragraph 5.7 below, the cost of the Appeal Panel must be paid entirely by the Appellant.

 

    	Page 5 

    	 

    

5.3Appeal
Procedure. The Appeal will be deemed an appeal of the entire Arbitration Award. In conducting the Appeal, the Appeal Panel shall conduct
a de novo review of all Claims described or otherwise set forth in the Arbitration Notice. Subject to the foregoing and all other provisions
of this Paragraph 5, the Appeal Panel shall conduct the Appeal in a manner the Appeal Panel considers appropriate for a fair and expeditious
disposition of the Appeal, may hold one or more hearings and permit oral argument, and may review all previous evidence and discovery,
together with all briefs, pleadings and other documents filed with the Original Arbitrator (as well as any documents filed with the Appeal
Panel pursuant to Paragraph 5.4(a) below). Notwithstanding the foregoing, in connection with the Appeal, the Appeal Panel shall not permit
the parties to conduct any additional discovery or raise any new Claims to be arbitrated, shall not permit new witnesses or affidavits,
and shall not base any of its findings or determinations on the Original Arbitrator’s findings or the Arbitration Award.

5.4Timing.

(a)Within
seven (7) calendar days of the Appeal Commencement Date, the Appellant (i) shall deliver or cause to be delivered to the Appeal Panel
copies of the Appeal Notice, all discovery conducted in connection with the Arbitration, and all briefs, pleadings and other documents
filed with the Original Arbitrator (which material Appellee shall have the right to review and supplement if necessary), and (ii) may,
but is not required to, deliver to the Appeal Panel and to the Appellee a Memorandum in Support of the Appellant’s arguments concerning
or position with respect to all Claims, counterclaims, issues, or accountings presented or pleaded in the Arbitration. Within seven (7)
calendar days of the Appellant’s delivery of the Memorandum in Support, as applicable, the Appellee shall deliver to the Appeal
Panel and to the Appellant a Memorandum in Opposition to the Memorandum in Support. Within seven (7) calendar days of the Appellee’s
delivery of the Memorandum in Opposition, as applicable, the Appellant shall deliver to the Appeal Panel and to the Appellee a Reply Memorandum
to the Memorandum in Opposition. If the Appellant shall fail to substantially comply with the requirements of clause (i) of this subparagraph
(a), the Appellant shall lose its right to appeal the Arbitration Award, and the Arbitration Award shall be final. If the Appellee shall
fail to deliver the Memorandum in Opposition as required above, or if the Appellant shall fail to deliver the Reply Memorandum as required
above, then the Appellee or the Appellant, as the case may be, shall lose its right to so deliver the same, and the Appeal shall proceed
regardless.

(b) Subject
to subparagraph (a) above, the parties hereby agree that the Appeal must be heard by the Appeal Panel within thirty (30) calendar days
of the Appeal Commencement Date, and that the Appeal Panel must render its decision within thirty (30) calendar days after the Appeal
is heard (and in no event later than sixty (60) calendar days after the Appeal Commencement Date).

5.5Appeal
Panel Award. The Appeal Panel shall issue its decision (the “Appeal Panel Award”) through the lead arbitrator on
the Appeal Panel. Notwithstanding any other provision contained herein, the Appeal Panel Award shall (a) supersede in its entirety and
make of no further force or effect the Arbitration Award (provided that any protective orders issued by the Original Arbitrator shall
remain in full force and effect), (b) be final and binding upon the parties, with no further rights of appeal, (c) be the sole and exclusive
remedy between the parties regarding any Claims, counterclaims, issues, or accountings presented or pleaded in the Arbitration, and (d)
be promptly payable in United States dollars free of any tax, deduction or offset (with respect to monetary awards). Any costs or fees,
including without limitation attorneys’ fees, incurred in connection with or incident to enforcing the Appeal Panel Award shall,
to the maximum extent permitted by law, be charged against the party resisting such enforcement. The Appeal Panel Award shall include
Default Interest (with respect to monetary awards) at the rate specified in the Note for Default Interest both before and after the Arbitration
Award. Judgment upon the Appeal Panel Award will be entered and enforced by a state or federal court sitting in Salt Lake County, Utah.

5.6Relief.
The Appeal Panel shall have the right to award or include in the Appeal Panel Award any relief which the Appeal Panel deems proper
under the circumstances, including, without limitation, specific performance and injunctive relief, provided that the Appeal Panel may
not award exemplary or punitive damages.

5.7Fees
and Costs. As part of the Appeal Panel Award, the Appeal Panel is hereby directed to require the losing party (the party being awarded
the least amount of money by the arbitrator, which, for the avoidance of doubt, shall be determined without regard to any statutory fines,
penalties, fees, or other charges awarded to any party) to (a) pay the full amount of any unpaid costs and fees of the Arbitration and
the Appeal Panel, and (b) reimburse the prevailing party (the party being awarded the most amount of money by the Appeal Panel, which,
for the avoidance of doubt, shall be determined without regard to any statutory fines, penalties, fees, or other charges awarded to any
part) the reasonable attorneys’ fees, arbitrator and Appeal Panel costs and fees, deposition costs, other discovery costs, and other
expenses, costs or fees paid or otherwise incurred by the prevailing party in connection with the Arbitration (including without limitation
in connection with the Appeal).

 

    	Page 6 

    	 

    

6. Miscellaneous.

6.1Severability.
If any part of these Arbitration Provisions is found to violate or be illegal under applicable law, then such provision shall be modified
to the minimum extent necessary to make such provision enforceable under applicable law, and the remainder of the Arbitration Provisions
shall remain unaffected and in full force and effect.

6.2Governing
Law. These Arbitration Provisions shall be governed by the laws of the State of Utah without regard to the conflict of laws principles
therein.

6.3Interpretation.
The headings of these Arbitration Provisions are for convenience of reference only and shall not form part of, or affect the interpretation
of, these Arbitration Provisions.

6.4Waiver.
No waiver of any provision of these Arbitration Provisions shall be effective unless it is in the form of a writing signed by the party
granting the waiver.

6.5Time
is of the Essence. Time is expressly made of the essence with respect to each and every provision of these Arbitration Provisions.

[Remainder of page intentionally left blank]

 

 

 

    	Page 7Exhibit 10.3

 

 

Secured Promissory
Note

 

	Effective Date: May 20, 2022	U.S. $6,015,000.00

 

FOR VALUE RECEIVED, Nemaura
Medical Inc., a Nevada corporation (“Company”), Dermal Diagnostics Limited,
an England and Wales corporation (“Dermal Diagnostics”), and Trial Clinic Limited,
an England and Wales corporation (“Trial Clinic,” and together with Dermal Diagnostics, “Borrower”),
jointly and severally promise to pay to Streeterville Capital, LLC, a Utah limited liability
company, or its successors or assigns (“Lender”), $6,015,000.00 and any fees, charges, and late fees accrued hereunder
on the date that is twenty-four (24) months after the Purchase Price Date (the “Maturity Date”) in accordance with
the terms set forth herein. This Secured Promissory Note (this “Note”) is issued and made effective as of May 20, 2022
(the “Effective Date”). This Note is issued pursuant to that certain Note Purchase Agreement dated May 20, 2022, as
the same may be amended from time to time, by and between Borrower and Lender (the “Purchase Agreement”). Certain capitalized
terms used herein are defined in Attachment 1 attached hereto and incorporated herein by this reference.

This Note carries an OID
of $1,000,000.00. In addition, Borrower agrees to pay $15,000.00 to Lender to cover Lender’s legal fees, accounting costs, due diligence,
monitoring and other transaction costs incurred in connection with the purchase and sale of this Note (the “Transaction Expense
Amount”), all of which amount is fully earned and included in the initial principal balance of this Note. The purchase price
for this Note shall be $5,000,000.00 (the “Purchase Price”), computed as follows: $6,015,000.00 original principal
balance, less the OID, less the Transaction Expense Amount. The Purchase Price shall be payable by Lender by wire transfer of immediately
available funds.

1.
Payment; Prepayment; Monitoring Fee.

1.1.
Payment. All payments owing hereunder shall be in lawful money of the United States of America
and delivered to Lender at the address or bank account furnished to Borrower for that purpose. All payments shall be applied first to
(a) costs of collection, if any, then to (b) fees and charges, if any, then to (c) accrued and unpaid monitoring fees, and thereafter,
to (d) principal. 

1.2.
Prepayment. Borrower shall have the right to prepay all or any portion of the Outstanding
Balance. If Borrower exercises its right to prepay this Note, Borrower shall make payment to Lender of an amount in cash equal to 110%
multiplied by the portion of the Outstanding Balance Borrower elects to prepay.

1.3.
Monitoring Fee. Beginning on June 1, 2022 and continuing on the first day of each month thereafter
until this Note has been paid in full, a monitoring fee equal to 0.833% of the then-current Outstanding Balance will automatically be
added to the Outstanding Balance. 

2.
Security. This Note is secured by the Security Agreement (as defined in the Purchase Agreement),
executed by Borrower in favor of Lender encumbering the collateral set forth therein, as more specifically set forth in the Security Agreement,
all the terms and conditions of which are hereby incorporated into and made a part of this Note. 

3.
Redemption. Beginning on the date that is six (6) months after the Purchase Price Date, Lender
shall have the right, exercisable at any time in its sole and absolute discretion, to redeem any amount of this Note up to the Maximum
Monthly Redemption Amount (such amount, the “Redemption Amount”) per calendar month by providing written notice to
Borrower (each, a “Redemption Notice”). For the avoidance of doubt, Lender may submit to Borrower one (1) or more
Redemption Notices in any given calendar month so long as the aggregate amount being redeemed in such month does not exceed the Maximum
Monthly Redemption Amount. Upon receipt of any Redemption Notice, Borrower shall pay the applicable Redemption Amount in cash to Lender
within five (5) Trading Days of Borrower’s receipt of such Redemption Notice. 

    	1 

    	 

    

4.
Defaults and Remedies.

4.1.
Defaults. The following are events of default under this Note (each, an “Event of
Default”): (a) Borrower fails to pay any principal, monitoring or other fees, charges, or any other amount when due and payable
hereunder; (b) a receiver, trustee or other similar official shall be appointed over Borrower or a material part of its assets and such
appointment shall remain uncontested for twenty (20) days or shall not be dismissed or discharged within sixty (60) days; (c) Borrower
becomes insolvent or generally fails to pay, or admits in writing its inability to pay, its debts as they become due, subject to applicable
grace periods, if any; (d) Borrower makes a general assignment for the benefit of creditors; (e) Borrower files a petition for relief
under any bankruptcy, insolvency or similar law (domestic or foreign); (f) an involuntary bankruptcy proceeding is commenced or filed
against Borrower; (g) Borrower or any pledgor, trustor, or guarantor of this Note defaults or otherwise fails to observe or perform any
covenant, obligation, condition or agreement of Borrower or such pledgor, trustor, or guarantor contained herein or in any other Transaction
Document (as defined in the Purchase Agreement); (h) the occurrence of a Fundamental Transaction without Lender’s prior written
consent; (i) any representation, warranty or other statement made or furnished by or on behalf of Borrower or any pledgor, trustor, or
guarantor of this Note to Lender herein, in any Transaction Document, or otherwise in connection with the issuance of this Note is false,
incorrect, incomplete or misleading in any material respect when made or furnished; and (j) any United States money judgment, writ or
similar process is entered or filed against Borrower or any subsidiary of Borrower or any of its property or other assets for more than
$1,000,000.00, and shall remain unvacated, unbonded or unstayed for a period of twenty (20) calendar days unless otherwise consented to
by Lender. The occurrence of any event described above in Section 4.1(g) – (j) shall not be considered an Event of Default hereunder
if such event is cured within fifteen (15) days of the occurrence thereof. 

4.2.
Remedies. At any time and from time to time after Lender becomes aware of the occurrence of
any Event of Default, Lender may accelerate this Note by written notice to Borrower, with the Outstanding Balance becoming immediately
due and payable in cash at the Mandatory Default Amount. Notwithstanding the foregoing, at any time following the occurrence of any Event
of Default, Lender may, at its option, elect to increase the Outstanding Balance by applying the Default Effect (subject to the limitation
set forth below) via written notice to Borrower without accelerating the Outstanding Balance, in which event the Outstanding Balance shall
be increased as of the date of the occurrence of the applicable Event of Default pursuant to the Default Effect, but the Outstanding Balance
shall not be immediately due and payable unless so declared by Lender (for the avoidance of doubt, if Lender elects to apply the Default
Effect pursuant to this sentence, it shall reserve the right to declare the Outstanding Balance immediately due and payable at any time
and no such election by Lender shall be deemed to be a waiver of its right to declare the Outstanding Balance immediately due and payable
as set forth herein unless otherwise agreed to by Lender in writing). Notwithstanding the foregoing, upon the occurrence of any Event
of Default described in clauses (b), (c), (d), (e) or (f) of Section 4.1, the Outstanding Balance as of the date of acceleration shall
become immediately and automatically due and payable in cash at the Mandatory Default Amount, without any written notice required by Lender.
At any time following the occurrence of any Event of Default, upon written notice given by Lender to Borrower, monitoring fees shall accrue
on the Outstanding Balance beginning on the date the applicable Event of Default occurred at a rate equal to the lesser of twenty-two
percent (22%) per annum or the maximum rate permitted under applicable law (“Default Monitoring Fees”). In connection
with acceleration described herein, Lender need not provide, and Borrower hereby waives, any presentment, demand, protest or other notice
of any kind, and Lender may immediately and without expiration of any grace period enforce any and all of its rights and remedies hereunder
and all other remedies available to it under applicable law. Such acceleration may be rescinded and annulled by Lender at any time prior
to payment hereunder and Lender shall have all rights as a holder of the Note until such time, if any, as Lender receives full payment
pursuant to this Section 4.2. No such rescission or annulment shall affect any subsequent Event of Default or impair any right consequent
thereon. Nothing herein shall limit Lender’s right to pursue any other remedies available to it at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief.

5.
Unconditional Obligation; No Offset. Borrower acknowledges that this Note is an unconditional,
valid, binding and enforceable obligation of Borrower not subject to offset, deduction or counterclaim of any kind. Borrower hereby waives
any rights of offset it now has or may have hereafter against Lender, its successors and assigns, and agrees to make the payments called
for herein in accordance with the terms of this Note.

 

    	2 

    	 

    

6.
Waiver. No waiver of any provision of this Note shall be effective unless it is in the form
of a writing signed by the party granting the waiver. No waiver of any provision or consent to any prohibited action shall constitute
a waiver of any other provision or consent to any other prohibited action, whether or not similar. No waiver or consent shall constitute
a continuing waiver or consent or commit a party to provide a waiver or consent in the future except to the extent specifically set forth
in writing.

7.
Opinion of Counsel. In the event that an opinion of counsel is needed for any matter related
to this Note, Lender has the right to have any such opinion provided by its counsel. 

8.
Governing Law; Venue. This Note shall be construed and enforced in accordance with, and all
questions concerning the construction, validity, interpretation and performance of this Note shall be governed by, the internal laws of
the State of Utah, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of Utah or any
other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Utah. The provisions set
forth in the Purchase Agreement to determine the proper venue for any disputes are incorporated herein by this reference.

9.
Arbitration of Disputes. By its issuance or acceptance of this Note, each party agrees to
be bound by the Arbitration Provisions (as defined in the Purchase Agreement) set forth as an exhibit to the Purchase Agreement.

10.
Cancellation. After repayment of the entire Outstanding Balance, this Note shall be deemed
paid in full, shall automatically be deemed canceled, and shall not be reissued.

11.
Amendments. The prior written consent of both parties hereto shall be required for any change
or amendment to this Note.

12.
Assignments. Borrower may not assign this Note without the prior written consent of Lender.
This Note may be offered, sold, assigned or transferred by Lender without the consent of Borrower, so long as such transfer is in accordance
with applicable federal and state securities laws.

13.
Notices. Whenever notice is required to be given under this Note, unless otherwise provided
herein, such notice shall be given in accordance with the subsection of the Purchase Agreement titled “Notices.”

14.
Liquidated Damages. Lender and Borrower agree that in the event Borrower fails to comply with
any of the terms or provisions of this Note, Lender’s damages would be uncertain and difficult (if not impossible) to accurately
estimate because of the parties’ inability to predict future rates, future share prices, future trading volumes and other relevant
factors. Accordingly, Lender and Borrower agree that any fees, balance adjustments, Default Monitoring Fees or other charges assessed
under this Note are not penalties but instead are intended by the parties to be, and shall be deemed, liquidated damages.

15.
Severability. If any part of this Note is construed to be in violation of any law, such part
shall be modified to achieve the objective of Borrower and Lender to the fullest extent permitted by law and the balance of this Note
shall remain in full force and effect.

16.
Joint and Several Obligations. To the extent applicable, any references in this Note to Borrower
refer to each person or entity constituting Borrower jointly and severally, and all promises, agreements, covenants, waivers, consents,
representations, warranties, and other provisions in this Note are made by and are binding upon each such undersigned person or entity,
jointly and severally.

[Remainder of page intentionally left blank; signature
page follows]

 

    	3 

    	 

    

 

IN WITNESS WHEREOF, Borrower
has caused this Note to be duly executed as of the Effective Date.

BORROWER:

Nemaura
Medical Inc.

 

 

By: /s/ Dewan F.H. Chowdhury

Name: Dewan F.H. Chowdhury

Title: CEO

 

 

Dermal
Diagnostics Limited

 

 

By: /s/ Dewan F.H. Chowdhury

Name: Dewan F.H. Chowdhury

Title: Director

 

 

Trial
Clinic Limited

 

 

By: /s/ Dewan F.H. Chowdhury

Name: Dewan F.H. Chowdhury

Title: Director

 

 

ACKNOWLEDGED, ACCEPTED AND AGREED:

LENDER:

Streeterville
Capital, LLC

 

 

By: /s/ John M. Fife

John M. Fife, President

 

 

 

 

 

    	 

    	 

    

ATTACHMENT 1

DEFINITIONS

 

For purposes of this
Note, the following terms shall have the following meanings:

A1.
“Default Effect” means multiplying the Outstanding Balance as of the date the Event of Default occurred by ten
percent (10%).

A2.
“DTC” means the Depository Trust Company or any successor thereto.

A3.
“DTC/FAST Program” means the DTC’s Fast Automated Securities Transfer program.

A4.
“DWAC” means the DTC’s Deposit/Withdrawal at Custodian system.

A5.
“DWAC Eligible” means that (a) Company’s Common Stock is eligible at DTC for full services pursuant to
DTC’s operational arrangements, including without limitation transfer through DTC’s DWAC system; (b) Company has been approved
(without revocation) by DTC’s underwriting department; (c) Company’s transfer agent is approved as an agent in the DTC/FAST
Program; and (d) Company’s transfer agent does not have a policy prohibiting or limiting delivery of Common Stock via DWAC.

A6.
“Fundamental Transaction” means that (a) (i) Borrower or any of its subsidiaries shall, directly or indirectly,
in one or more related transactions, consolidate or merge with or into (whether or not Borrower or any of its subsidiaries is the surviving
corporation) any other person or entity, or (ii) Borrower or any of its subsidiaries shall, directly or indirectly, in one or more
related transactions, sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of its respective
properties or assets to any other person or entity, or (iii) Borrower or any of its subsidiaries shall, directly or indirectly, in
one or more related transactions, allow any other person or entity to make a purchase, tender or exchange offer that is accepted by the
holders of more than 50% of the outstanding shares of voting stock of Borrower (not including any shares of voting stock of Borrower held
by the person or persons making or party to, or associated or affiliated with the persons or entities making or party to, such purchase,
tender or exchange offer), or (iv) Borrower or any of its subsidiaries shall, directly or indirectly, in one or more related transactions,
consummate a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off or scheme of arrangement) with any other person or entity whereby such other person or entity acquires more than 50% of the outstanding
shares of voting stock of Borrower (not including any shares of voting stock of Borrower held by the other persons or entities making
or party to, or associated or affiliated with the other persons or entities making or party to, such stock or share purchase agreement
or other business combination), or (v) Borrower or any of its subsidiaries shall, directly or indirectly, in one or more related
transactions, reorganize, recapitalize or reclassify the Common Stock, other than an increase in the number of authorized shares of Borrower’s
Common Stock, or reverse splits of its outstanding and authorized shares of Common Stock to meet Nasdaq listing requirements or (b) any
“person” or “group” (as these terms are used for purposes of Sections 13(d) and 14(d) of the 1934 Act and the
rules and regulations promulgated thereunder) is or shall become the “beneficial owner” (as defined in Rule 13d-3 under
the 1934 Act), directly or indirectly, of 50% of the aggregate ordinary voting power represented by issued and outstanding voting stock
of Borrower.

A7.
“Mandatory Default Amount” means the Outstanding Balance following the application of the Default Effect.

A8.
“Maximum Monthly Redemption Amount” means $100,000.00 until April 30, 2023 and $500,000.00 thereafter.

A9.
“OID” means an original issue discount.

A10.
“Other Agreements” means, collectively, (a) all existing and future agreements and instruments between, among
or by Borrower (or an affiliate), on the one hand, and Lender (or an affiliate), on the other hand, and (b) any financing agreement or
a material agreement that affects Borrower’s ongoing business operations.

A11.
“Outstanding Balance” means as of any date of determination, the Purchase Price, as reduced or increased, as
the case may be, pursuant to the terms hereof for payment, offset, or otherwise, plus the OID, the Transaction Expense Amount, accrued
but unpaid monitoring fees, collection and enforcements costs (including attorneys’ fees) incurred by Lender, transfer, stamp, issuance
and similar taxes and fees incurred under this Note.

 

    	 

    	 

    

A12.
“Purchase Price Date” means the date the Purchase Price is delivered by Lender to Borrower.

A13.
“Trading Day” means any day on which the New York Stock Exchange (or such other principal market for the Common
Stock) is open for trading. For purposes of determining Borrower’s cash payment deadline under this Note, such “Trading Day”
shall exclude any day on which banking institutions in Dalian, China are authorized or required by law or other governmental action to
close.

 

[Remainder of page intentionally
left blank]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]